Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 10.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to be listed under the symbol “ERNA.” Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 16.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 20.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 01.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 05.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Rule 5605(c)(4). Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Of |
| 26.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nal Form 8-K. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
| 31.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 10.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | C. Binder and Richard W. Wagner, as disclosed in Item 5.02 of this Current Report on Form 8-K, the Company no longer com |
| 11.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 05.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 26.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 04.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
Stammdaten
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Ernexa Therapeutics Inc. |
|---|---|
| Ticker | ERNA |
| CIK | 0000748592 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,5 Mio. USD |
| Beta | 6,85 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -14,084,000 | -2.24 | 5,834,000 | 2,401,000 | |
| 2025-09-30 | 10-Q | -1,240,000 | -0.15 | 6,172,000 | 3,570,000 | |
| 2025-06-30 | 10-Q | -3,139,000 | -0.61 | 7,584,000 | 4,443,000 | |
| 2025-03-31 | 10-Q | -8,202,000 | -0.15 | 5,059,000 | -5,950,000 | |
| 2024-12-31 | 10-K | 582,000 | -44,539,000 | -48.96 | 5,269,000 | 1,701,000 |
| 2024-09-30 | 10-Q | 487,000 | -26,604,000 | -73.70 | 7,718,000 | -45,393,000 |
| 2024-06-30 | 10-Q | 47,000 | -5,529,000 | -15.34 | 46,486,000 | -8,526,000 |
| 2024-03-31 | 10-Q | 47,000 | -6,647,000 | -1.23 | 49,657,000 | -3,412,000 |
| 2023-12-31 | 10-K | 68,000 | -21,668,000 | -4.08 | 49,132,000 | 2,233,000 |
| 2023-09-30 | 10-Q | 51,000 | -5,591,000 | -1.03 | 52,248,000 | 3,562,000 |
| 2023-06-30 | 10-Q | -4,508,000 | -0.85 | 46,954,000 | 3,866,000 | |
| 2023-03-31 | 10-Q | 0 | -5,416,000 | -1.06 | 15,108,000 | 7,380,000 |
| 2022-12-31 | 10-K | 0 | -24,579,000 | -8.06 | 22,279,000 | 12,107,000 |
| 2022-09-30 | 10-Q | 0 | -7,316,000 | -2.49 | 20,926,000 | 8,813,000 |
| 2022-06-30 | 10-Q | -3,398,000 | -1.16 | 26,902,000 | 14,778,000 | |
| 2022-03-31 | 10-Q | -9,375,000 | -3.50 | 35,376,000 | 17,311,000 | |
| 2021-12-31 | 10-K | -122,545,000 | -56.61 | 31,525,000 | 25,503,000 | |
| 2021-09-30 | 10-Q | -85,986,000 | -34.03 | 39,394,365 | 31,530,000 | |
| 2021-06-30 | 10-Q | -10,085,000 | -0.24 | 64,709,646 | 53,603,000 | |
| 2021-03-31 | 10-Q | -18,522,000 | -0.67 | 20,698,076 | 13,999,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | Cherington Charles | 10% Owner | Open Market Purchase | 4,000,000 | 0.50 | 2,000,000.00 | +94,7% | |
| 2025-06-09 | Cherington Charles | 10% Owner | Open Market Purchase | 21,241,163 | 0.10 | 2,221,825.65 | +105,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.